Research and Markets: Examine The Chinese Pharmaceutical Industry As It Increased With An Annual Average Growth Rate Of 16.72% Over The Last Few Decades

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/336f84/chinese_pharmaceut) has
announced the addition of the "Chinese Pharmaceutical Industry" report to their
offering.

The Chinese pharmaceutical industry has increased with an annual average growth
rate of 16.72% over the last few decades. However, the industry is still
small-scale, with a scattered geographical layout, duplicated production
processes, and outdated manufacturing technology and management structure. The
Chinese pharmaceutical industry also has a lower market concentration and weak
international trading competitiveness, coupled with a lack of patented
pharmaceuticals developed in-house. Gaining access to the WTO will further
integrate the Chinese economy into the global economic environment, and Chinese
pharmaceutical enterprises will face a huge challenge.

China's entry into the WTO, in December of 2001, opened the door to a lucrative
market for foreign companies, and especially for pharmaceutical manufacturers
and distributors. Accession to the WTO will bind China by fundamental WTO
principles, such as improved transparency and the strengthening of commercial
legal procedures. China's WTO commitments also include the tightening of rules
on intellectual property, tariff concessions, and permission of foreign
distributors' entry into domestic market. These commitments will help reduce the
risk of doing business in China and encourage increased flow of trade and
investment, enhancing the business opportunities for international
pharmaceutical companies and investors.

This study provides a comprehensive analysis of the multifaceted pharmaceutical
industry and market, based on full and accurate statistics, help guide for
non-Chinese companies and investors through the many changes transforming the
Chinese pharmaceutical sector.

Key Topics Covered:

Executive summary

Foreword - Professor Xiaoming Wu, Chancellor, China Pharmaceutical University

Introduction

An overview of the pharmaceutical industry in China

* Economic reform and the open door policy in context
* The growth of the Chinese pharmaceutical industry
* The structure of the Chinese pharmaceutical industry
* R&D in China
* Marketing approvals and manufacturing
* Non-Chinese investment enterprises in China

Competing in the international market

* Introduction
* Measuring trading competitiveness
* Potential trading competitiveness

Business opportunities for non-Chinese pharmaceutical firms in China

* Factors affecting business opportunities in China
* The factors bringing business opportunities
* How to capture business opportunities
* Which would be the profitable fields for non-Chinese pharmaceutical firms?

Conclusion

Appendices

Companies Mentioned:

* Sino-Swed Pharmaceutical Corp.LTD (SSPC)
* Pfizer (China) Pharmaceuticals Limited

For more information visit
http://www.researchandmarkets.com/research/336f84/chinese_pharmaceut

Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Copyright Business Wire 2009